83 / 140 · Strongest daily foundation, no telomere mechanism

The strongest competitor here and the closest thing to a genuine daily foundation outside Protocol 01. Spermidine at 10 mg is a real autophagy dose, Ca-AKG at 2 g is the highest in the set, and the probiotic gives Blueprint the best dysbiosis coverage in the comparison. Publishing batch-level certificates of analysis sets a standard the rest of the category should be held to.

With 36 marketed actives it still contains no cycloastragenol and no astragalus of any kind. Glucoraphanin at 20 mg with no myrosinase makes NRF2 activation largely theoretical at that dose, and the two-format structure creates daily friction with no unitisation.

79 / 140 · Best senolytic, thinnest daily foundation

Two companies in one bundle. The Senolytic, at 1,400 mg fisetin with a quercetin phytosome and lipid-optimised curcumin, is the most potent consumer senolytic available and now carries a peer-reviewed publication. The Stem Cell product is the only serious attempt at that driver in this set.

Then the daily product: 300 mg NR, 234 mg niacinamide, 50 mg resveratrol and filler, which is one pathway running for roughly 80 percent of the month inside a formula whose niacinamide works against its own resveratrol. Four regimen changes inside a single month, and 28 servings per container rather than 30.

77 / 140 · Lowest friction, narrowest coverage

The best commercial execution in the category and the lowest-friction product in it. One scoop, one drink, NSF Certified for Sport, and the best-reviewed flavour among the powders.

The formula is ten ingredients addressing roughly a quarter of the aging framework. Three drivers are legitimately strong. Everything else is moderate, weak or absent: no telomere compound, no NRF2 system, no methylation cycle, no pulsed senolytic, no dysbiosis support.

77 / 140 · Best human evidence, narrowest formulation

NOVOS has the best human evidence of any product here and it is not close. Their finished formula was tested in a randomised, double-blind, placebo-controlled trial of 61 adults aged 40 and over at the University of Surrey, showing improvements against placebo in flow-mediated dilation, pulse wave velocity and systolic blood pressure at six months. Testing the finished formula rather than citing studies of its parts is the harder and more expensive path.

The formulation is narrower than the evidence is deep. Core carries no NAD+ precursor, NMN is sold separately as Boost, and there is no telomere compound and no pulsed layer. Taste is a real adherence risk: roughly 3.8 g of bitter or sour actives in a 15 g serving, masked with stevia alone.

59 / 140 · Highest burden, internal formulation conflict

Protocol 01 leads Tally Health on fourteen of fifteen metrics. The exception is palatability, where both are all-capsule and score equally.

The most damaging finding is internal: 1,000 mg of niacinamide in the NAD+ product taken alongside 500 mg of resveratrol in Vitality, both part of the same recommended daily stack. Spermidine sits at roughly a tenth of the effective dose, and 420 capsules a month across six bottles is the highest burden here by a wide margin. The TallyAge epigenetic test is a legitimate tool, and following the April 2026 acquisition the diagnostic capability behind the brand is now considerably stronger than the formulation in front of it.